We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
+252.95%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4M
AUM Growth
-$3.18M
Cap. Flow
-$13.7M
Cap. Flow %
-83.98%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$157K

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$13.4M
2
TSBX
Turnstone Biologics
TSBX
+$322K
3
THRD
Third Harmonic Bio
THRD
+$200K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
1
Ovid Therapeutics
OVID
$489M
$9.79M 59.82%
7,531,996
– –
EQ icon
2
Equillium
EQ
$138M
$2.61M 15.94%
1,824,977
– –
XLO icon
3
Xilio Therapeutics
XLO
$59.9M
$1.24M 7.59%
105,366
– –
STTK icon
4
Shattuck Labs
STTK
$704M
$1.23M 7.53%
515,619
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$330M
$891K 5.45%
54,887
+13,722
+33% +$157K
AMWL icon
6
American Well
AMWL
$221M
$478K 2.92%
77,733
– –
RANI icon
7
Rani Therapeutics
RANI
$87.7M
$102K 0.62%
203,190
– –
LAB icon
8
Standard BioTools
LAB
$307M
$21.5K 0.13%
16,515
– –
HLVX
9
DELISTED
HilleVax
HLVX
– –
-6,724,000
Closed -$13.4M
THRD
10
DELISTED
Third Harmonic Bio
THRD
– –
-36,835
Closed -$200K
TSBX
11
DELISTED
Turnstone Biologics
TSBX
– –
-895,824
Closed -$322K

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q3 2025 Portfolio in Review

As of Q3 2025, Takeda Pharmaceutical Company held 11 positions worth $16.4M, down 16% from $19.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Takeda Pharmaceutical Company withdrew a net $13.7M in Q3 2025, closing 3 positions. Its most notable exit was HilleVax, an estimated $13.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Takeda Pharmaceutical Company added an estimated $157K to Lyell Immunopharma.

  • Takeda Pharmaceutical Company added most to Lyell Immunopharma in Q3 2025, an estimated $157K increase.
  • Takeda Pharmaceutical Company fully exited HilleVax in Q3 2025, selling an estimated $13.4M.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $16.4M portfolio in Q3 2025.
  • Takeda Pharmaceutical Company opened 0 new positions and closed 3 in Q3 2025.
  • Takeda Pharmaceutical Company's portfolio value fell 16% quarter-over-quarter to $16.4M.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.